N-terminal proatrial natriuretic peptide in angina pectoris: Impact of revascularization by angioplasty

International Journal of Cardiology

Volumn 68, Issue 1, 1999, Pages 1-8

  Klinge, Randi ^a   Jørgensen, Bjørn ^b   Thaulow, Erik ^b   Sirnes, Per Anton ^c   Hall, Christian ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c Feiring Heart Clinic   (Norway)

Author keywords

Angioplasty; Atrial natriuretic peptide; Coronary disease

Indexed keywords

ATRIAL NATRIURETIC FACTOR DERIVATIVE; HORMONE PRECURSOR;

ADULT; AMINO TERMINAL SEQUENCE; ANGINA PECTORIS; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HORMONE DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PEPTIDE ANALYSIS; PRIORITY JOURNAL; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADULT; AGE FACTORS; AGED; AMLODIPINE; ANGINA PECTORIS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ATRIAL NATRIURETIC FACTOR; CALCIUM CHANNEL BLOCKERS; CHRONIC DISEASE; CORONARY DISEASE; CREATININE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; RADIOIMMUNOASSAY; STATISTICS, NONPARAMETRIC;

EID: 0032932184     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(98)00342-8     Document Type: Article

References (30)

1. Edwards B.S., Zimmerman R.S., Schwab T.R., Heublein D.M., Burnett J.C. Jr. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res. 62:1988;191-195.
2. Dietz J.R., Nazian S.J., Vesely D.L. Release of ANF, N-terminal proANP 1-98, and N-terminal proANP 31-67 from isolated rat atria by atrial distension. Am J Physiol. 260:1991;H1774-H1778.
3. Matsubara H., Nishikawa M., Umeda Y.et al. The role of atrial pressure in secreting atrial natriuretic polypeptides. Am Heart J. 113:1987;1457-1463.
4. Nakamura M., Kawata Y., Yoshida H.et al. Relationship between plasma atrial and brain natriuretic peptide concentration and hemodynamic parameters during percutaneous transvenous mitral valvulotomy in patients with mitral stenosis. Am Heart J. 124:1992;1283-1288.
5. Mathisen P., Hall C., Simonsen S. Comparative study of atrial peptides ANF(1-98) and ANF(99-126) as diagnostic markers of atrial distension in patients with cardiac disease. Scand J Clin Lab Invest. 53:1993;41-49.
6. Hall C., Kjekshus J., Eneroth P., Snapinn S. The plasma concentration of N-terminal proatrial natriuretic factor ANF (1-98) is related to prognosis in severe heart failure. Clin Cardiol. 17:1994;191-195.
7. Dickstein K., Larsen A.I., Bonarjee V., Thoresen M., Aarsland T., Hall C. Plasma proatrial natriuretic factor is predictive of clinical status in patients with congestive heart failure. Am J Cardiol. 76:1995;679-683.
8. Lerman A., Gibbons R.J., Rodeheffer R.J.et al. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet. 341:1993;1105-1109.
9. Cowie M., Struthers A.D., Wood D.A.et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 350:1997;1349-1353.
10. Itoh H., Nakao K., Sugawara A.et al. Gamma-atrial natriuretic polypeptide (gammaANP)-derived peptides in human plasma: cosecretion of N-terminal gammaANP fragment and alfaANP. J Clin Endocrinol Metab. 67:1988;429-437.
11. Sundsfjord J.A., Thibault G., Larochelle P., Cantin M. Identification and plasma concentrations of the N-terminal fragment of proatrial natriuretic factor in man. J Clin Endocrinol Metab. 66:1988;605-610.
12. Nelesen R.A., Dimsdale J.E., Ziegler M.G. Plasma atrial natriuretic peptide is unstable under most storage conditions. Circulation. 86:1992;463-466.
13. Hall C., Aaberge L., Stokke O. In vitro stability of N-terminal proatrial natriuretic factor in unfrozen samples: an important prerequisite for its use as a biochemical parameter of atrial pressure in clinical routine. Circulation. 91:1995;911.
14. Uusimaa P.A., Ikäheimo M.J., Ruskoaho H.et al. Release of atrial natriuretic peptide in relation to metabolic changes during myocardial ischaemia induced by coronary angioplasty. Eur Heart J. 14:1993;682-686.
15. Ikäheimo M., Ruskoaho H.J., Airaksinen J.et al. Plasma levels of atrial natriuretic peptide during myocardial ischemia induced by percutaneous transluminal coronary angioplasty or dynamic exercise. Am Heart J. 117:1989;837-841.
16. Gill J.S., Prasad K., Stewart J.T.et al. Acute changes in atrial natriuretic peptide, insulin-like growth factor-1, and lactate levels during left anterior descending coronary artery angioplasty. Am Heart J. 130:1995;717-722.
17. Malatino L., Leonardi C., Stancanelli B.et al. Transient myocardial ischemia stimulates atrial natriuretic factor release. Am Heart J. 123:1992;693-698.
18. Thaulow E., Jørgensen B. Clinical promise of calcium antagonists in the angioplasty patients. Eur Heart J. 18(Suppl B):1997;B21-B26.
19. Serruys PW. In: Serruys PW, Foley DP, DeFeyter PJ, editors. Quantitative coronary angiography in clinical practise. Dordrecht: Kluwer Academic, 1994.
20. Donckier J.E., De Coster P.M., Buysschaert M.et al. Effect of beta-adrenergic blockade on plasma atrial natriuretic factor and cardiac volumes during exercise in normal man. Am J Cardiol. 63:1989;1000-1002.
21. Yoshimoto T., Naruse M., Tanabe A.et al. Potentiation of natriuretic peptide action by the beta-adrenergic blocker carvedilol in hypertensive rats: a new antihypertensive mechanism. Endocrinology. 139:1998;81-88.
22. Linderer T., Guhl B., Spielberg C., Wunderlich W., Schnitzer L., Schroder R. Effect on global and regional left ventricular functions by percutaneous transluminal coronary angioplasty in the chronic stage after myocardial infarction. Am J Cardiol. 69:1992;997-1002.
23. Perry R., Singh A., Seth A.et al. Sustained improvement in left ventricular function after successful coronary angioplasty. Br Heart J. 63:1990;277-280.
24. Lewis J., Verani M.S., Poliner L.R., Lewis J.M., Raizner A.E.R. Effects of transluminal coronary angioplasty on left ventricular systolic and diastolic function at rest and during exercise. Am Heart J. 109:1985;792-798.
25. Kent K., Bonow R.O., Rosing D.R.et al. Improved myocardial function during exercise after successful percutaneous transluminal coronary angioplasty. New Engl J Med. 306:1982;441-446.
26. Bonow R., Kent K.M., Rosing D.R.et al. Improved left ventricular diastolic filling in patients with coronary artery disease after percutaneous transluminal angioplasty. Circulation. 66:1982;1159-1167.
27. Serruys P.W., Foley D.P., Kirkeeide R.L., King S.B. Restenosis revisited: insights provided by quantitative coronary angiography. Am Heart J. 126:1993;1243-1267.
28. Kyriakides Z.S., Markianos M., Iliodromitis E.K., Kremastinos D.T. Vein plasma endothelin-1 and cyclic GMP increase during coronary angioplasty is related to myocardial ischemia. Eur Heart J. 16:1995;894-898.
29. Ameli S., Kaul S., Castro L., Arora C., Mirea A., Shah P.K. Effect of percutaneous transluminal coronary angioplasty on circulating endothelin levels. Am J Cardiol. 72:1993;1352-1356.
30. McCance A.J., Forfar J.C. Coronary venous noradrenaline during coronary angioplasty. Int J Cardiol. 33:1991;89-97.